General Information of Drug (ID: DMM149N)

Drug Name
PHA-568487 Drug Info
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Preclinical [1]
Cross-matching ID
PubChem CID
9932000
CAS Number
CAS 527680-56-4
TTD Drug ID
DMM149N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ziprasidone DMM58JY Bipolar disorder 6A60 Approved [3]
ALCURONIUM DM2U4XQ Anaesthesia 9A78.6 Approved [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [5]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [6]
EVP-6124 DMLQO7F Alzheimer disease 8A20 Phase 3 [7]
GTS-21 DMEN5KA Parkinson disease 8A00.0 Phase 2 [8]
JNJ-39393406 DMUOEKM Depression 6A70-6A7Z Phase 2 [9]
ABT-126 DM2OS51 Alzheimer disease 8A20 Phase 2 [10]
TC-6987 DMNFP21 Asthma CA23 Phase 2 [11]
AQW-051 DMD2RFO Alzheimer disease 8A20 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Agonist [2]

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018656)
2 Multiple species metabolism of PHA-568487, a selective alpha 7 nicotinic acetylcholine receptor agonist. Drug Metab Lett. 2010 Aug;4(3):162-72.
3 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
4 Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
5 Clinical pipeline report, company report or official report of Roche (2009).
6 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
7 Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
8 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
9 Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
10 A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
11 ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
12 AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.